Login to Your Account



Argos Therapeutics shares punished by HIV immunotherapy stumble

By Michael Fitzhugh
Staff Writer

Friday, January 9, 2015
Argos Therapeutics Inc. shares (NASDAQ:ARGS) fell 32.3 percent to $6.51 Friday – dipping below the company's $8 February 2014 initial public offering price – after top-line data from a phase IIb study showed that AGS-004, the company's personalized immunotherapy for HIV, failed to reduce median viral load more than a placebo in HIV-infected patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription